The recent European Medicines Agency marketing authorisation for belzutifan offers patients with renal cell carcinoma a well-tolerated and effective option for third- and fourth-line treatment. Future studies will assess its efficacy in earlier disease stages.
European urology. 2025 May 16 [Epub ahead of print]
Catherine Graham, Laurence Albiges, Marc-Oliver Grimm, Thomas Powles
Barts Cancer Institute, London, UK., Institut Gustave Roussy, Université Paris Saclay, Villejuif, France., Department of Urology, Jena University Hospital, Jena, Germany., Barts Cancer Institute, London, UK. Electronic address: .